Comparative Pharmacology
Head-to-head clinical analysis: MONISTAT 3 versus MONISTAT 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MONISTAT 3 versus MONISTAT 7.
MONISTAT 3 vs MONISTAT 7
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Miconazole nitrate, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Miconazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, reducing ergosterol synthesis and disrupting fungal cell membrane integrity.
One vaginal suppository (200 mg miconazole nitrate) intravaginally at bedtime for 3 consecutive days; or one applicatorful (5 g) of 4% vaginal cream intravaginally at bedtime for 7 days.
Intravaginal administration of 100 mg miconazole nitrate suppository once daily at bedtime for 7 days.
None Documented
None Documented
Terminal elimination half-life is approximately 30 hours after topical vaginal application; prolonged in hepatic impairment.
Terminal elimination half-life is approximately 24-30 hours following intravaginal administration; clinical significance: supports once-daily dosing.
Primarily fecal (97%) via biliary excretion; renal excretion of unchanged drug is negligible (<1%).
Primarily via feces (approximately 87-93% of dose) as unchanged drug and metabolites; renal excretion negligible (<1%).
Category C
Category C
Antifungal
Antifungal